Literature DB >> 16284461

Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?

Amanda Mocroft1, Vincent Soriano, Jurgen Rockstroh, Peter Reiss, Ole Kirk, Stephane de Wit, Jose Gatell, Bonaventura Clotet, Andrew N Phillips, Jens D Lundgren.   

Abstract

BACKGROUND: Increases in deaths due to liver-related disease (LRD) among HIV-infected individuals have been reported although the influence of combination antiretroviral therapy (cART) on LRD is controversial. AIMS: To determine changes over time in the death rate from LRD and if longer exposure to cART was associated with an increased death rate from LRD in 10 937 patients from EuroSIDA, an observational longitudinal cohort study.
RESULTS: A total of 184 (1.7%) died from LRD during 52 236 person-years of follow-up (PYFU). The death rate from LRD declined from 6.9 per 1000 PYFU before 1995 [95% confidence interval (CI), 3.9-9.9] to 2.6 at/after 2004 (95% CI, 1.6-4.0). When the current CD4 cell count and other factors were taken into account, there was a 13% increase in the death rate from LRD per year (95% CI, 5-20%, P = 0.0008). In patients who had started cART, there was a 12% increase in the death rate from LRD per additional year exposure to cART (95% CI, 4-20%, P = 0.022) after adjustment for current CD4 cell count and other factors.
CONCLUSIONS: Death rates from LRD appeared to decrease across Europe. However after adjustment for the current CD4 cell count, and therefore increases in CD4 cell counts in patients taking cART, there was a significant increase over time in death rates from LRD. In patients with similar CD4 cell counts, longer exposure to cART was associated with an increased death rate from LRD. This may be due to direct liver toxicity of antiretrovirals, progression of liver disease due to hepatitis B virus or hepatitis C virus over time as patients survive longer, or some other factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284461     DOI: 10.1097/01.aids.0000194799.43799.ea

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

Review 1.  Solid organ transplantation is a reality for patients with HIV infection.

Authors:  Michelle E Roland; Peter G Stock
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

2.  Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

Authors:  José Moltó; Marta Valle; Asunción Blanco; Eugenia Negredo; Meritxell DelaVarga; Cristina Miranda; José Miranda; Pere Domingo; Josep Vilaró; Cristina Tural; Joan Costa; Manuel José Barbanoj; Bonaventura Clotet
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.

Authors:  Valentina Li Vecchi; Maurizio Soresi; Claudia Colomba; Giovanni Mazzola; Pietro Colletti; Maurizio Mineo; Paola Di Carlo; Emanuele La Spada; Giovanni Vizzini; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

4.  Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy.

Authors:  M De Paschale; M T Manco; L Belvisi; C Magnani; T Re; P Viganò; S Biagiotti; F Capelli; A Mazzone; M P Baldacci; A Ferrara; A L Neri; C M Guastoni; R A Bonazzina; B Brando; P Clerici
Journal:  Infection       Date:  2012-02-25       Impact factor: 3.553

5.  The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.

Authors:  William J Towner; Lanfang Xu; Wendy A Leyden; Michael A Horberg; Chun R Chao; Beth Tang; Daniel B Klein; Leo B Hurley; Charles P Quesenberry; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

6.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

7.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 8.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

9.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

10.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.